Jpmorgan Chase & CO Precision Biosciences Inc Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$0.29 - $0.45 $70,416 - $109,266	242,815 New	242,815 $87,000
Q4 2023 Feb 12, 2024	SELL	$0.29 - $0.45 $49,363 - $76,598	-170,218 Reduced 41.21%	242,815 $87,000
Q3 2023 Nov 14, 2023	SELL	$0.34 - $0.69 $568,975 - $1.15 Million	-1,673,456 Reduced 80.2%	413,033 $140,000
Q2 2023 Aug 11, 2023	SELL	$0.52 - $0.91 $10,928 - $19,125	-21,017 Reduced 1.0%	2,086,489 $1.11 Million
Q1 2023 May 11, 2023	BUY	$0.7 - $1.41 $362,391 - $729,959	517,702 Added 32.56%	2,107,506 $1.58 Million
Q4 2022 Feb 13, 2023	BUY	$0.97 - $45.0 $18,873 - $875,565	19,457 Added 1.24%	1,589,804 $1.89 Million
Q3 2022 Nov 14, 2022	BUY	$1.22 - $40.8 $809,723 - $27.1 Million	663,708 Added 73.21%	1,570,347 $2.04 Million
Q2 2022 Aug 11, 2022	BUY	$1.15 - $3.34 $313 - $911	273 Added 0.03%	906,639 $1.45 Million
Q1 2022 May 11, 2022	BUY	$2.96 - $7.76 $487,855 - $1.28 Million	164,816 Added 22.23%	906,366 $2.79 Million
Q4 2021 Feb 10, 2022	SELL	$7.4 - $11.66 $1.17 Million - $1.85 Million	-158,251 Reduced 17.59%	741,550 $5.49 Million
Q3 2021 Nov 12, 2021	BUY	$9.18 - $14.15 $8.26 Million - $12.7 Million	899,801 New	899,801 $10.4 Million

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $422M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.